Kiran Nistala Acquires 3,195 Shares of Zura Bio Limited (NASDAQ:ZURA) Stock

Zura Bio Limited (NASDAQ:ZURA) EVP Kiran Nistala acquired 3,195 shares of Zura Bio stock in a transaction dated Monday, April 22nd. The shares were purchased at an average price of $3.13 per share, for a total transaction of $10,000.35. Following the completion of the transaction, the executive vice president now directly owns 3,195 shares in the company, valued at approximately $10,000.35. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Zura Bio Stock Performance

ZURA opened at $3.62 on Friday. Zura Bio Limited has a 1 year low of $2.00 and a 1 year high of $14.00. The stock’s 50 day simple moving average is $3.19 and its 200 day simple moving average is $4.03.

Institutional Investors Weigh In On Zura Bio

Several institutional investors and hedge funds have recently bought and sold shares of ZURA. Armistice Capital LLC lifted its holdings in Zura Bio by 66.3% in the 3rd quarter. Armistice Capital LLC now owns 1,580,000 shares of the company’s stock worth $10,428,000 after buying an additional 630,000 shares during the period. Silverarc Capital Management LLC lifted its holdings in Zura Bio by 152.5% in the 3rd quarter. Silverarc Capital Management LLC now owns 404,040 shares of the company’s stock worth $2,667,000 after buying an additional 244,040 shares during the period. Eisler Capital US LLC purchased a new stake in Zura Bio in the 3rd quarter worth approximately $660,000. Bank of New York Mellon Corp purchased a new stake in Zura Bio in the 3rd quarter worth approximately $224,000. Finally, Forefront Analytics LLC purchased a new stake in Zura Bio in the 3rd quarter worth approximately $95,000. Hedge funds and other institutional investors own 61.14% of the company’s stock.

Analysts Set New Price Targets

Separately, Oppenheimer reiterated an “outperform” rating and set a $16.00 price objective (down from $17.00) on shares of Zura Bio in a research report on Monday, April 1st. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $16.40.

About Zura Bio

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.